Education
About Us
Working with TipRanks
Follow Us
Integrum AB Class B (DE:6Y1)
FRANKFURT:6Y1
6Y1 Stock Chart & Stats
€0.94
-€0.06(-3.43%)
At close: 4:00 PM EST
€0.94
-€0.06(-3.43%)
Day’s Range― - ―
52-Week Range€0.64 - €3.86
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€17.83M
Enterprise Value€136.20M
Total Cash (Recent Filing)€30.17M
Total Debt (Recent Filing)€3.60M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Jun 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding26,027,910
10 Day Avg. Volume6
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.64
Price to Sales (P/S)3.20
P/FCF Ratio-5.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low debt and a solid equity base materially reduce near-term solvency risk and preserve strategic optionality. Over 2–6 months this supports funding operations, incremental commercialization or clinical rollout without immediate refinancing pressure, improving resilience while cash burn issues are addressed.
Niche, High-barrier Product OfferingOPRA’s focus on osseointegration and direct-skeleton prosthetic attachment represents a specialized technology with clinical adoption barriers and concentrated provider networks. That niche positioning creates durable competitive advantages: high switching costs, clinical specialization and structural demand from amputee rehabilitation needs.
Demonstrated Path To Profitability HistoricallyAchieving positive EBIT/EBITDA and net income in 2024 shows the business model can scale to profitability under the right conditions. This indicates operational leverage exists and management can reach breakeven, making a sustainable recovery plausible if revenue growth or cost control improves.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow increases funding risk and limits the company’s ability to self-fund commercialization, clinical support and R&D. Over months this can force dilutive equity raises or constrained investment, delaying adoption and prolonging the path to sustainable profitability.
Flat-to-declining RevenueRevenue roughly flat to down signals limited commercial momentum and weak top-line scalability. Without durable revenue growth, operating leverage cannot be realized and fixed costs pressure margins, making it harder to convert clinical technology advantages into sustainable cash generation over the medium term.
Earnings Instability And Negative ReturnsVolatile earnings—profitability in 2024 followed by large losses in 2025 and TTM—indicate unstable execution or market adoption issues. Negative ROE shows the equity base isn't generating returns, complicating capital allocation and investor confidence and increasing the risk that structural issues persist absent clear operational fixes.
Integrum AB Class B News
6Y1 FAQ
What was Integrum AB Class B’s price range in the past 12 months?
Integrum AB Class B lowest stock price was €0.64 and its highest was €3.86 in the past 12 months.
What is Integrum AB Class B’s market cap?
Integrum AB Class B’s market cap is €17.83M.
When is Integrum AB Class B’s upcoming earnings report date?
Integrum AB Class B’s upcoming earnings report date is Jun 05, 2026 which is in 76 days.
How were Integrum AB Class B’s earnings last quarter?
Integrum AB Class B released its earnings results on Mar 02, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.043.
Is Integrum AB Class B overvalued?
According to Wall Street analysts Integrum AB Class B’s price is currently Overvalued.
Does Integrum AB Class B pay dividends?
Integrum AB Class B does not currently pay dividends.
What is Integrum AB Class B’s EPS estimate?
Integrum AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrum AB Class B have?
Integrum AB Class B has 26,027,910 shares outstanding.
What happened to Integrum AB Class B’s price movement after its last earnings report?
Integrum AB Class B reported an EPS of -€0.043 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.91%.
Which hedge fund is a major shareholder of Integrum AB Class B?
Currently, no hedge funds are holding shares in DE:6Y1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrum AB Class B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. The company also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was founded in 1962 and is headquartered in Mölndal, Sweden.